- Home
- BAK vs GPCR Comparison
BAK vs GPCR Comparison
Compare BAK & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAK
- GPCR
- Stock Information
- Founded
- BAK 1972
- GPCR 2016
- Country
- BAK Brazil
- GPCR United States
- Employees
- BAK N/A
- GPCR N/A
- Industry
- BAK Major Chemicals
- GPCR
- Sector
- BAK Industrials
- GPCR
- Exchange
- BAK Nasdaq
- GPCR Nasdaq
- Market Cap
- BAK 1.7B
- GPCR 1.8B
- IPO Year
- BAK N/A
- GPCR 2023
- Fundamental
- Price
- BAK $4.11
- GPCR $27.30
- Analyst Decision
- BAK Strong Buy
- GPCR Buy
- Analyst Count
- BAK 3
- GPCR 6
- Target Price
- BAK $9.75
- GPCR $85.67
- AVG Volume (30 Days)
- BAK 1.2M
- GPCR 797.2K
- Earning Date
- BAK 11-06-2024
- GPCR 11-13-2024
- Dividend Yield
- BAK N/A
- GPCR N/A
- EPS Growth
- BAK N/A
- GPCR N/A
- EPS
- BAK N/A
- GPCR N/A
- Revenue
- BAK $13,764,416,401.00
- GPCR N/A
- Revenue This Year
- BAK $14.26
- GPCR N/A
- Revenue Next Year
- BAK $8.26
- GPCR N/A
- P/E Ratio
- BAK N/A
- GPCR N/A
- Revenue Growth
- BAK 2.86
- GPCR N/A
- 52 Week Low
- BAK $4.07
- GPCR $29.48
- 52 Week High
- BAK $10.98
- GPCR $62.74
- Technical
- Relative Strength Index (RSI)
- BAK 27.12
- GPCR 35.94
- Support Level
- BAK $4.07
- GPCR $30.81
- Resistance Level
- BAK $4.35
- GPCR $36.42
- Average True Range (ATR)
- BAK 0.22
- GPCR 2.10
- MACD
- BAK -0.05
- GPCR -0.15
- Stochastic Oscillator
- BAK 11.76
- GPCR 25.07
About BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.